Literature DB >> 19689963

Evaluation of inelastic hadronic processes for 250 MeV proton interactions in tissue and iron using GEANT4.

Y Chen1, S Ahmad.   

Abstract

When high-energy protons interact in beam delivery systems and are stopped in patients, a fraction of beam will undergo nuclear interactions that release secondary particles, in particular, neutrons of different energies. The GEANT4 Monte Carlo Code was used to simulate the interaction of 250 MeV proton beam in tissue and iron to calculate the energy and angular distributions of generated protons, neutrons and photons, and thus provide H* (10), the ambient dose equivalent. A modular physics list by utilising electromagnetic interactions and hadronic interactions was constructed. Three different GEANT4 models that include the low-energy parameterisation, binary cascade and pre-compound model with Bertini cascade for proton inelastic interactions were compared. The findings suggest that the models play critical roles in terms of secondary particle generation. Further benchmarks are necessary to select the best model predicting a realistic scenario.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689963     DOI: 10.1093/rpd/ncp149

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  3 in total

Review 1.  Monte Carlo methods for device simulations in radiation therapy.

Authors:  Hyojun Park; Harald Paganetti; Jan Schuemann; Xun Jia; Chul Hee Min
Journal:  Phys Med Biol       Date:  2021-09-14       Impact factor: 4.174

2.  Dose and linear energy transfer distributions of primary and secondary particles in carbon ion radiation therapy: A Monte Carlo simulation study in water.

Authors:  Daniel Johnson; Yong Chen; Salahuddin Ahmad
Journal:  J Med Phys       Date:  2015 Oct-Dec

3.  Shielding verification and neutron dose evaluation of the Mevion S250 proton therapy unit.

Authors:  Michael T Prusator; Salahuddin Ahmad; Yong Chen
Journal:  J Appl Clin Med Phys       Date:  2018-02-22       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.